Solos Endoscopy Posts Shareholder Update on OTC Markets.com
January 10 2014 - 02:43PM
Marketwired
Solos Endoscopy Posts Shareholder Update on OTC Markets.com
BOSTON, MA--(Marketwired - Jan 10, 2014) - Solos Endoscopy, Inc.
(OTC Pink: SNDY) a provider of quality innovative healthcare
instruments to Hospitals across the Country, posted an update for
the shareholders on OTC Markets.com.
The Company posted a letter
from the President on the OTC Markets website
(http://www.otcmarkets.com/financialReportViewer?symbol=SNDY&id=115342)
Solos Endoscopy completed the
Audit with TUV SUD America this past year, which included a
comprehensive review of the Solos Endoscopy's Quality Manual and 28
Quality System Procedures for compliance with the international
quality system standard ISO 13485:2003, to the European Union's
Medical Device Directive (MDD 93/42/EEC) and to the Canadian
Medical Device Regulations (SOR/98-282). Since the completion of
the Audit, the Company has been in contact with the representatives
from both TUV SUD and Expert Resources and expects to be certified
to ISO 13485:2003 in the next few weeks. Certification to ISO
13485:2003 will in turn allow Solos Endoscopy to obtain the CE Mark
on the majority of endoscopic instruments including the MammoView®
devices.
Solos has several exciting new advances in product development
that will change the way minimally invasive procedures are utilized
in the medical field in order to treat and prevent disease. These
products will allow the physician to examine organs and tissues
within the body without the need for intrusive surgery. The Company
is currently marketing its next generation breast endoscopy system,
the MammoView® system, for early breast cancer detection.
About Solos Endoscopy, Inc.:
Solos Endoscopy celebrated its 25th Year of providing quality
innovative healthcare instruments to Hospitals across the Country.
For more than 25 Years, from medical schools to hospitals, surgeons
have trusted Solos Endoscopy to develop and market breakthrough
technology, applications, medical devices, and procedural
techniques for the screening, diagnosis, treatment and management
of disease and medical conditions. Additional information on its
FDA approved products is available on the Company's website at:
www.solosendoscopy.com.
Certain statements in this news release may contain
forward-looking information within the meaning of Rule 175 under
the Securities Act of 1933 and Rule 3b-6 under the Securities
Exchange Act of 1934, and are subject to the safe harbor created by
those rules. All statements, other than statements of fact,
included in this release, including, without limitation, statements
regarding potential future plans and objectives of the company, are
forward-looking statements that involve risks and uncertainties.
There can be no assurance that such statements will prove to be
accurate and actual results and future events could differ
materially from those anticipated in such statements. Technical
complications that may arise could prevent the prompt
implementation of any strategically significant plan(s) outlined
above. The company cautions that these forward-looking statements
are further qualified by other factors including, but not limited
to, those set forth in the company's Annual Report filing and other
filings with the OTC Markets Group (available at
www.otcmarkets.com). The company undertakes no obligation to
publicly update or revise any statements in this release, whether
as a result of new information, future events, or otherwise.
Solos Endoscopy, Inc. Investor Relations (617) 360-9719